Analyst Ratings For NASDAQ:ADMP – Adamis Pharmaceuticals (NASDAQ:ADMP)
Today, HC Wainwright initiated coverage on NASDAQ:ADMP – Adamis Pharmaceuticals (NASDAQ:ADMP) with a Buy.
Some recent analyst ratings include
- 4/23/2018-HC Wainwright initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:ADMP – Adamis Pharmaceuticals (NASDAQ:ADMP)
NASDAQ:ADMP – Adamis Pharmaceuticals (NASDAQ:ADMP) has insider ownership of 12.20% and institutional ownership of 12.39%.
- On 6/2/2016 David J Marguglio, VP, sold 700 with an average share price of $9.00 per share and the total transaction amounting to $6,300.00.
- On 5/16/2016 David J Marguglio, SVP, sold 4,000 with an average share price of $8.08 per share and the total transaction amounting to $32,320.00.
- On 5/9/2016 David J Marguglio, SVP, sold 4,860 with an average share price of $10.00 per share and the total transaction amounting to $48,600.00.
- On 5/4/2016 David J Marguglio, SVP, sold 4,860 with an average share price of $9.17 per share and the total transaction amounting to $44,566.20.
- On 5/3/2016 David J Marguglio, SVP, sold 1,140 with an average share price of $9.00 per share and the total transaction amounting to $10,260.00.
- On 4/14/2016 David J Marguglio, SVP, sold 12,000 with an average share price of $7.52 per share and the total transaction amounting to $90,240.00.
- On 8/14/2015 Robert B Rothermel, Director, bought 7,000 with an average share price of $3.33 per share and the total transaction amounting to $23,310.00.
Recent Trading Activity for NASDAQ:ADMP – Adamis Pharmaceuticals (NASDAQ:ADMP)
Shares of NASDAQ:ADMP – Adamis Pharmaceuticals closed the previous trading session at with 84537 shares trading hands.